Dated: September 11, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–22991 Filed 9–14–95; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Division of Research Grants; Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: September 28, 1995.

Time: 5:00 p.m.

Place: NIH, Rockledge II, Room 6170,

Telephone Conference.

Contact Person: Dr. Dennis E. Leszczynski, Scientific Review Administrator, 6701 Rockledge Drive, Room 6170, Bethesda, MD 20892, (301) 435–1044.

Name of SEP: Biological and Physiological Sciences.

Date: September 29, 1995.

Time: 4:00 p.m.

Place: NIH, Rockledge II, Room 6170,

Telephone Conference.

Contact Person: Dr. Dennis E. Leszczynski, Scientific Review Administrator, 6701 Rockledge Drive, Room 6170, Bethesda, MD 20892, (301) 435–1044.

Name of SEP: Clinical Sciences.

Date: October 5, 1995.

Time: 1:00 p.m.

Place: NIH, Rockledge II, Room 4128,

Telephone Conference.

Contact Person: Dr. Anshumali Chaudhari, Scientific Review Administrator, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435–1210.

Name of SEP: Multidisciplinary Sciences.

Date: October 29-31, 1995.

Time: 6:00 p.m.

Place: New Haven, CT.

Contact Person: Dr. Nadarajen

Vydelingum, Scientific Review

Administrator, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435–1176.

Name of SEP: Multidisciplinary Sciences. *Date:* October 29–30, 1995.

Time: 7:00 p.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Lee Rosen, Scientific Review Administrator, 6701 Rockledge Drive, Room 5116, Bethesda, MD 20892, (301) 435– 1171

Name of SEP: Multidisciplinary Sciences.

Date: November 5–7, 1995.

Time: 7:00 p.m.

Place: Marriott LA Airport Hotel, Los

Angeles, CA.

Contact Person: Dr. Nabeeh Mourad, Scientific Review Administrator, 6701 Rockledge Drive, Room 5110, Bethesda, MD 20892, (301) 435–1168.

Name of SEP: Multidisciplinary Sciences.

Date: November 8-10, 1995.

Time: 6:00 p.m.

Place: Sheraton Metrodome Hotel,

Minneapolis, MN.

Contact Person: Dr. Bill Bunnag, Scientific Review Administrator, 6701 Rockledge Drive, Room 5112, Bethesda, MD 20892, (301) 435– 1177

Name of SEP: Multidisciplinary Sciences.

Date: November 15–17, 1995.

Time: 6:00 p.m.

Place: St. Louis, Missouri.

Contact Person: Dr. Bill Bunnag, Scientific Review Administrator, 6701 Rockledge Drive, Room 5212, Bethesda, MD 20892, (301) 435– 1177.

Name of SEP: Multidisciplinary Sciences.

Date: November 19-21, 1995.

Time: 7:00 p.m.

Place: Woods Hole, Massachusetts.

Contact Person: Dr. Nadarajen

Vydelingum, Scientific Review

Administrator, 6701 Rockledge Drive, Room 5210, Bethesda, Maryland 20892, (301) 435–

Purpose/Agenda: To review Small Business Innovation Research.

Name of SEP: Multidisciplinary Sciences.

Date: October 22–24, 1995.

Time: 7:00 p.m.

Place: La Guardia Marriott Hotel, New York, NY.

Contact Person: Dr. Nabeeh Mourad, Scientific Review Administrator, 6701 Rockledge Drive, Room 5110, Bethesda, Maryland 20892, (301) 435–1168.

Name of SEP: Multidisciplinary Sciences. Date: October 30–November 1, 1995. Time: 7:00 a.m.

Place: Bethesda Marriott Hotel, Bethesda, Maryland.

Contact Person: Dr. Nabeeh Mourad, Scientific Review Administrator, 6701 Rockledge Drive, Room 5110, Bethesda, Maryland 20892, (301) 435–1168.

Name of SEP: Multidisciplinary Sciences. *Date:* November 5–7, 1995.

Time: 4:00 p.m.

Place: Holiday Inn, Chevy Chase,

Maryland.

Contact Person: Dr. Nadarajen Vydelingum, Scientific Review Administrator, 6701 Rockledge Drive, Room 5210, Bethesda, Maryland 20892, (301) 435– 1176.

Name of SEP: Multidisciplinary Sciences. *Date:* November 6–7, 1995.

Time: 8:00 a.m.

Place: Doubletree Hotel, Rockville, Maryland.

Contact Person: Dr. Nancy Shinowara, Scientific Review Administrator, 6701 Rockledge Drive, Room 5216, Bethesda, Maryland 20892, (301) 435–1173.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade

secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393– 93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 11, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.
[FR Doc. 95–22990 Filed 9–14–95; 8:45 am]
BILLING CODE 4140–01–M

[Docket No.]

Prospective Grant of Exclusive License: Veterinary Vaccine and Therapeutic Uses of Bartonella Henselae (Formerly Rochalimaea Henselae) Organisms

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patents and patent applications referred to below to Paravax, Inc., having a place of business in Fort Collins, Colorado. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are: "Methods and Compositions for Diagnosing Cat Scratch Disease and Bacillary Angiomatosis Caused by Rochalimaea henselae," U.S. Patent Application Serial No. 07/822,539 filed 17 Jan 92 (U.S. Patent No. 5,399,485 issued 21 Mar 95) and related cases, which include all continuation applications, divisional applications, continuation-in-part applications, and foreign counterpart applications.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the